These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35300435)

  • 21. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit.
    Lanna C; Cesaroni GM; Mazzilli S; Vollono L; Gaziano R; Marino D; Bianchi L; Campione E
    J Dermatolog Treat; 2022 Mar; 33(2):1097-1101. PubMed ID: 32715817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
    Afra TP; Razmi TM; Dogra S
    Indian Dermatol Online J; 2019; 10(1):1-12. PubMed ID: 30775293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apremilast monotherapy for palmoplantar pustulosis: Report of three cases.
    Marovt M; Marko PB
    SAGE Open Med Case Rep; 2021; 9():2050313X211034926. PubMed ID: 34394938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
    Mease PJ
    Rheumatol Ther; 2014 Dec; 1(1):1-20. PubMed ID: 27747762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on the safety of apremilast for the treatment of plaque psoriasis.
    Shavit E; Shear NH
    Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
    [No Abstract]   [Full Text] [Related]  

  • 29. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Refractory palmoplantar pustulosis succesfully treated with apremilast.
    Carrascosa de Lome R; Conde Montero E; de la Cueva Dobao P
    Dermatol Ther; 2020 Mar; 33(2):e13230. PubMed ID: 31981290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Lespessailles E; Hall S; Hochfeld M; Hu C; Hough D; Stevens RM; Schett G
    Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
    Gisondi P; Girolomoni G
    Drug Des Devel Ther; 2016; 10():1763-70. PubMed ID: 27307707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
    J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apremilast as a treatment for psoriasis.
    Shutty B; West C; Pellerin M; Feldman S
    Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios.
    Rajagopalan M; Dogra S; Saraswat A; Varma S; Banodkar P
    Psoriasis (Auckl); 2021; 11():109-122. PubMed ID: 34430450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
    Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.